Petros Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Iroquois Capital Management and its principals, Richard Abbe and Kimberly Page, reported a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc. as of December 21, 2025.
OTC.Pink
Iroquois Capital Management and its principals disclose a continued 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., limited by beneficial ownership blockers.
OTC.Pink
SCHEDULE 13G/A: Iroquois Capital Management Discloses 9.99% Stake in Petros Pharmaceuticals, Limited by Ownership Blockers
Iroquois Capital Management, LLC, along with its principals Richard Abbe and Kimberly Page, has disclosed a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., constrained by pre-existing beneficial ownership blockers on warrants and preferred shares.
OTC.Pink
SCHEDULE 13G: Iroquois Capital Management and Affiliates Disclose Significant Passive Stake in Petros Pharmaceuticals
Iroquois Capital Management, Richard Abbe, and Kimberly Page have filed a Schedule 13G, revealing a combined beneficial ownership of up to 9.99% in Petros Pharmaceuticals, Inc., subject to beneficial ownership blockers.
OTC.Pink
SCHEDULE 13G/A: Investment Funds Disclose 6.2% Stake in Petros Pharmaceuticals
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have disclosed a combined beneficial ownership of 6.2% in Petros Pharmaceuticals, Inc. common stock as of December 31, 2024.